The compound you provided, **2-(2,5-dioxo-4,4-dipropyl-1-imidazolidinyl)-N-(3-methoxyphenyl)acetamide**, is a complex organic molecule with a specific structure. Its importance lies in its potential for **biological activity** and its role in **medicinal chemistry research**.
Here's a breakdown of its components and potential significance:
* **Imidazolidinyl ring:** This ring structure is common in various pharmaceuticals, including anticonvulsants, antivirals, and antifungal agents. Its presence suggests the compound could have a biological effect.
* **Dipropyl groups:** These branched alkyl chains can influence a molecule's solubility, membrane permeability, and interaction with biological targets.
* **Acetamide group:** This functional group often contributes to a molecule's ability to bind to enzymes or other biological receptors.
* **3-Methoxyphenyl group:** This aromatic group can also influence a molecule's interactions with biological systems.
**Why is it important for research?**
This compound could be a **lead compound** in drug discovery research. Lead compounds are molecules that exhibit some desired biological activity and can be further modified and optimized to create more effective and safe drugs.
**Potential research areas:**
* **Antimicrobial activity:** The imidazolidinyl ring is a known scaffold for antimicrobial agents, and this compound's structure could make it a potential candidate for the development of novel antibiotics.
* **Antiviral activity:** Similar to antimicrobial activity, the imidazolidinyl ring has been explored for its potential to inhibit viral replication.
* **Anti-inflammatory activity:** The molecule's structure could contribute to its ability to reduce inflammation, which is a significant target for drug development.
* **Neurological activity:** The presence of an acetamide group and an aromatic ring could suggest potential activity in the nervous system, potentially leading to therapeutic applications for neurological conditions.
**Note:** It's crucial to understand that without further research, the exact biological activity and importance of this compound are unknown. Research needs to be conducted to assess its properties, toxicity, and potential therapeutic value.
ID Source | ID |
---|---|
PubMed CID | 2089356 |
CHEBI ID | 116682 |
Synonym |
---|
MLS000058074 , |
smr000067497 |
CHEBI:116682 |
MLS002634925 |
2-(2,5-dioxo-4,4-dipropylimidazolidin-1-yl)-n-(3-methoxyphenyl)acetamide |
HMS2331P22 |
SR-01000056229-1 |
sr-01000056229 |
2-(2,5-dioxo-4,4-dipropyl-1-imidazolidinyl)-n-(3-methoxyphenyl)acetamide |
bdbm41230 |
2-[2,5-bis(oxidanylidene)-4,4-dipropyl-imidazolidin-1-yl]-n-(3-methoxyphenyl)ethanamide |
2-(2,5-diketo-4,4-dipropyl-imidazolidin-1-yl)-n-(3-methoxyphenyl)acetamide |
cid_2089356 |
Q27200997 |
Z14041350 |
AKOS033314130 |
Class | Description |
---|---|
imidazolidine-2,4-dione | An imidazolidinone with oxo groups at position 2 and 4. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
RNA polymerase beta subunit (EC 2.7.7.6), partial | Escherichia coli | IC50 (µMol) | 50.0000 | 11.6872 | 17.0900 | 23.7759 | AID826 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |